Text Request Honored with Inc. Power Partner Award for 2nd Year
October 24, 2023 07:33 ET
|
Text Request
CHATTANOOGA, TENN., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Text Request, the industry-leading business messaging platform, has been recognized as an Inc. Power Partner for the second year in a row....
Synthetic Cannabinoids Market Size & Share to Surpass $6.7 Billion by 2030 | Vantage Market Research
August 29, 2023 07:36 ET
|
Vantage Market Research
WASHINGTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- As per Vantage Market Research, the Global Synthetic Cannabinoids Market has been steadily growing over the years due to increasing demand for...
Barrack, Rodos & Bacine Investigates Napco Security Technologies, Inc. (NSSC)
August 24, 2023 09:30 ET
|
Barrack Rodos & Bacine
PHILADELPHIA, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Barrack, Rodos & Bacine (BR&B) is investigating Napco Security Technologies, Inc. (“Napco”) (NASDAQ: NSSC) for potential violations of federal...
Cardiometabolic Drugs Market revenue to exceed USD 72 Billion by 2035, says Research Nester
August 21, 2023 06:00 ET
|
Research Nester
New York, Aug. 21, 2023 (GLOBE NEWSWIRE) -- The global Cardiometabolic Drugs Market size is projected to expand at ~ 6% CAGR between 2023 and 2035. The market is expected to garner a revenue of USD...
EQUITY ALERT: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Edgio, Inc. f/k/a Limelight Networks, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EGIO, LLNW
April 27, 2023 12:23 ET
|
The Rosen Law Firm PA
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Edgio,...
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
April 04, 2023 17:15 ET
|
The Rosen Law Firm PA
NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update
February 17, 2023 17:00 ET
|
InMed Pharmaceuticals Inc.
Closed calendar year 2022 with strong cash position of $11.5 millionApproaches completion of enrollment for Ph 2 clinical trial in EBAdvances research using rare cannabinoids in treating glaucoma and...
InMed Submits Form 12b-25
February 09, 2023 21:41 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and...
Access Recognized in Two Categories by Inc.’s Prestigious Inaugural Power Partner Awards
January 24, 2023 11:30 ET
|
Access Information Management Shared Services, LLC
WOBURN, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Access, the world’s largest privately-held integrated information management services provider, today announced that it has been recognized by Inc....
InMed Provides Business Update and Milestones for 2023
January 10, 2023 07:30 ET
|
InMed Pharmaceuticals Inc.
Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023Progress preclinical research in glaucoma in preparation for human trialsAdvance research using rare cannabinoids in...